Latest Conference Articles

November 10th 2018, 11:29pm

PER® New York Lung Cancer Symposium

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.

November 10th 2018, 2:42am

PER® New York Lung Cancer Symposium

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

November 10th 2018, 2:04am

PER® New York Lung Cancer Symposium

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

November 9th 2018, 11:50pm

PER® New York Lung Cancer Symposium

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

November 9th 2018, 10:07pm

PER® New York Lung Cancer Symposium

Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.

November 9th 2018, 8:45pm

PER® New York Lung Cancer Symposium

Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.

November 9th 2018, 3:26am

State of the Science Summit on Hematologic Malignancies

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the use of maintenance and consolidation in multiple myeloma.

November 8th 2018, 12:31am

State of the Science Summit on Hematologic Malignancies

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

November 6th 2018, 10:03pm

State of the Science Summit on GI Malignancies

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the impact of peptide receptor radionuclide therapy (PRRT) on the treatment of patients with neuroendocrine tumors (NETs).

November 6th 2018, 10:01pm

State of the Science Summit on GI Malignancies

Afsaneh Barzi, MD, assistant professor of clinical medicine, Norris Comprehensive Cancer Center, University of Southern California, discusses available and emerging neoadjuvant strategies for the treatment of patients with nonmetastatic pancreatic cancer.

November 3rd 2018, 1:04am

State of the Science Summit on Hematologic Malignancies

Robert Dean, MD, staff physician, Cleveland Clinic, discusses the evolution of treatment approaches in mantle cell lymphoma (MCL).

October 31st 2018, 10:18pm

State of the Science Summit on GI Malignancies

Syma Iqbal, MD, discusses the evolving treatment paradigm of neuroendocrine tumors.

October 31st 2018, 12:03am

State of the Science Summit on GI Malignancies

The second-line treatment of gastric and gastroesophageal junction cancers has shifted considerably in the last few years, due in part to the addition of immunotherapy for select subgroups of patients.

October 26th 2018, 7:15pm

State of the Science Summit on Hematologic Malignancies

Brad Kahl, MD, discusses the rapidly evolving therapeutic landscape of CLL and the novel combinations on the horizon.

October 26th 2018, 6:54pm

State of the Science Summit on Hematologic Malignancies

Armin Ghobadi, MD, discusses the evolution and expansion of CAR T-cell therapy in oncology and how to maximize its application across liquid and solid tumors.

October 26th 2018, 6:22pm

State of the Science Summit on Hematologic Malignancies

Nancy L. Bartlett, MD, discusses factors in treatment decisions for patients with advanced-stage Hodgkin lymphoma.

October 26th 2018, 2:01am

State of the Science Summit on Hematologic Malignancies

Nancy Bartlett, MD, Koman Chair in Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses treatment regimens for patients with Hodgkin lymphoma.

October 26th 2018, 1:59am

State of the Science Summit on GI Malignancies

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

October 25th 2018, 5:24am

State of the Science Summit on Hematologic Malignancies

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the impact of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

October 25th 2018, 5:21am

ESMO Congress

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of the JAVELIN Renal 100 trial on the treatment landscape of renal cell carcinoma.